![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, April 09, 2007 2:16:17 PM
Did I miss any?
cmos
http://www.aacr.org/home/scientists/meetings--workshops/annual-meeting-2007.aspx
Abstract Number: 4095
Presentation Title: Selective targeting of cellular immune responses by
chimeric and humanized monoclonal antibodies to phosphatidylserine exposed
in tumor vasculature
Presentation Start/End Time: Tuesday, Apr 17, 2007, 8:00 AM -12:00 PM
Location: Exhibit Hall, Los Angeles Convention Center
Poster Section: 32
Poster Board Number: 10
Author Block: Monica Friedrich, Amy Brideau-Andersen, Bruce Freimark,
Connie Chang. Peregrine Pharmaceuticals, Inc., Tustin, CA
Abstract Number: 2128
Presentation Title: Blockade of tumor-derived VEGF activation of VEGF receptor 2
reduces macrophage infiltration into tumors and decreases metastasis in a
pre-clinical orthotopic model of pancreatic cancer
Presentation Start/End Time: Monday, Apr 16, 2007, 8:00 AM -12:00 PM
Location: Exhibit Hall, Los Angeles Convention Center
Poster Section: 20
Poster Board Number: 11
Author Block: Juliet G. Carbon, Shane E. Holloway, Andrew F. Miller,
Anita Kavlie, Kyle Schlunegger, Jason B. Fleming, Rolf A. Brekken. UT Southwestern
Medical Ctr., Dallas, TX, Affitech AS, Oslo, Norway,
Peregrine Pharmaceuticals Inc, Tustin, CA, UT-MD Anderson, Houston, TX
Abstract Number: 4091
Presentation Title: Enhancing the immunogenicity of glioma cells with
anti-phosphatidylserine antibody.
Presentation Start/End Time: Tuesday, Apr 17, 2007, 8:00 AM -12:00 PM
Location: Exhibit Hall, Los Angeles Convention Center
Poster Section: 32
Poster Board Number: 6
Author Block: Jin He, Troy A. Luster, Philip E. Thorpe. UT Southwestern
Medical Ctr., Dallas, TX
Abstract Number: 4092
Presentation Title: Targeting truncated tissue factor with tumor vasculature
specific monoclonal antibodies: developing coaguligands as cancer therapeutics
Presentation Start/End Time: Tuesday, Apr 17, 2007, 8:00 AM -12:00 PM
Location: Exhibit Hall, Los Angeles Convention Center
Poster Section: 32
Poster Board Number: 7
Author Block: Richard H. Archer, Mary Wakabayashi, Roy Sevilla, Scott Summers,
Steven King, Ronald T. Aimes. Peregrine Pharmaceuticals, Inc., Tustin, CA
Abstract Number: 4190
Presentation Title: Vasopermeation enhancement agents: A case study in screening
for the most potent variant in a new class of compounds by using a novel avian
embryonic system
Presentation Start/End Time: Tuesday, Apr 17, 2007, 12:10 PM -12:25 PM
Location: Room 515 A, Los Angeles Convention Center
Author Block: Kelly A. Felton, John D. Lewis, Andries Zijlstra, Jennifer Chase,
Keith A. Luhrs, Aparna I. Roy, Debra A. Harris, Christian Frosch, Steven W. King,
Missag H. Parseghian. Peregrine Pharmaceuticals, Tustin, CA, London Regional
Cancer Program, London, ON, Canada, Vanderbilt University, Nashville, TN,
Innovascreen, Halifax, NS, Canada, Biobroker, Hamburg, Germany
Abstract Number: 4089
Presentation Title: Fusion proteins composed of mouse IgG2a Fc and mouse
beta-2-glycoprotein 1 bind to endothelial cells with exposed phosphatidylserine
Presentation Start/End Time: Tuesday, Apr 17, 2007, 8:00 AM -12:00 PM
Location: Exhibit Hall, Los Angeles Convention Center
Poster Section: 32
Poster Board Number: 4
Author Block: Troy A. Luster, Philip E. Thorpe. Unversity of Texas Southwestern
Medical Center, Dallas, TX
Abstract Number: 3273
Presentation Title: Vascular targeting antibody improves chemotherapy of prostate
cancer
Presentation Start/End Time: Monday, Apr 16, 2007, 1:00 PM - 5:00 PM
Location: Exhibit Hall, Los Angeles Convention Center
Poster Section: 30
Poster Board Number: 5
Author Block: Yi Yin, Xianming Huang, Jin He, Troy A. Luster, Philip E. Thorpe.
UT Southwestern Medical Center, Dallas, TX
Abstract Number: 3539
Presentation Title: Inhibition of tumor growth by targeting cytokines to the
inside-out phosphatidylserine (PS) on tumor vascular endothelium with 2aG4
Presentation Start/End Time: Tuesday, Apr 17, 2007, 8:00 AM -12:00 PM
Location: Exhibit Hall, Los Angeles Convention Center
Poster Section: 8
Poster Board Number: 3
Author Block: Xianming Huang, Dan Ye, Philip Thorpe. UT Southwestern Medical Ctr.,
Dallas, TX
Recent CDMO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/09/2024 08:43:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:19:30 PM
- Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 • GlobeNewswire Inc. • 09/09/2024 08:05:31 PM
- U.S. Futures Rise Amid Inflation Report Anticipation; Oil Prices Climb on Hurricane Threat and Supply Concerns • IH Market News • 09/09/2024 10:09:14 AM
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:30:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/28/2024 08:34:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/28/2024 08:32:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
FEATURED Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • Sep 10, 2024 11:00 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM